Maze Therapeutics (MAZE) Gains from Investment Securities (2025 - 2026)

Maze Therapeutics' (MAZE) quarterly Gains from Investment Securities came in at $6.1 million in Q1 2026, up 15.11% year-on-year from $5.3 million in Q1 2025, and up 1870.1% quarter-over-quarter from $308350.0 in Q4 2025.

Maze Therapeutics (MAZE) Gains from Investment Securities (2025 - 2026) Analysis & Trends

Maze Therapeutics has disclosed Gains from Investment Securities across 2 years of filings, most recently posting $6.1 million for Q1 2026.

  • Gains from Investment Securities for Q1 2026 came in at $6.1 million, up 15.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (up 15.11% YoY), and the FY2025 annual result was $308350.0, changed N/A from the prior year.
  • Gains from Investment Securities came in at $6.1 million for Q1 2026 at Maze Therapeutics, up from $308350.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $6.1 million in Q1 2026 to a low of $308350.0 in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn -
7 Psyence Biomedical 229.39 Bn 229.38 Bn -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn
9 Abivax 90.15 Bn 90.15 Bn -
10 Maze Therapeutics 1.31 Bn 1.31 Bn 18.21 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 6.07 Mn
Mar 31, 2026 6.07 Mn
Dec 31, 2025 308,350.00
Dec 31, 2025 308,350.00
Sep 30, 2025 5.75 Mn
Sep 30, 2025 5.75 Mn
Jun 30, 2025 5.35 Mn
Jun 30, 2025 5.35 Mn
Mar 31, 2025 5.28 Mn
Mar 31, 2025 5.28 Mn